natgillin/translations-raw huggingface dataset:
c The interim PFS numbers have been updated based on a recalculation of the original data. 
c Vmesne vrednosti PFS (preživetje brez napredovanja bolezni) so posodobili na podlagi preračunanih originalnih podatkov.
Your doctor may check your blood pressure during treatment with Sutent, and you may be treated with medicines to reduce the blood pressure, if needed. 
Med zdravljenjem z zdravilom Sutent bo zdravnik morda preverjal vaš krvni tlak in če bo treba, vas bodo zdravili z zdravili za zniževanje krvnega tlaka.
In order to rule out bias in the investigator-based assessment of PFS, a BICR of scans was performed; this review supported the investigator assessment, as shown in Table 4. 
Da bi izključili pristranskost pri ocenjevanju PFS, ki so ga izvajali raziskovalci, so opravili slepo neodvisno centralno preverjanje pregledov; to preverjanje je podprlo ocene raziskovalcev, kot je prikazano v Preglednici 4.
a 2-sided unstratified log-rank test b 
2-stranski nestratificiran log-rang test
In the 807 patients who received long-term sunitinib treatment, most treatment-related adverse events (TRAEs) occurred initially in the first 6 months-1 year and then were stable or decreased in frequency over time, with the exception of hypothyroidism, which gradually increased over time, with new cases occurring over the 6 year period. 
Pri 807 bolnikih, ki so se dolgotrajno zdravili s sunitinibom, se je večina z zdravljenjem povezanih neželenih učinkov (TRAEs - treatment-related adverse events) najprej pojavila v obdobju prvih 6 mesecev do 1 leta, ki so nato ostali nespremenjeni oziroma se je njihova pogostnost s časom zmanjševala, z izjemo hipotiroidizma, katerega pogostnost se je s časom postopno povečala, saj so se v 6-letnem obdobju pojavili novi primeri.
- If you have had a recent problem with blood clots in your veins and/or arteries (types of blood vessels), including stroke, heart attack, embolism, or thrombosis. 
- Če ste imeli pred kratkim težave s krvnimi strdki v venah in/ali arterijah (vrste krvnih žil), vključno z možgansko kapjo, srčnim infarktom, embolijo ali trombozo.
Sunitinib inhibits multiple RTKs that are implicated in tumour growth, neoangiogenesis, and metastatic progression of cancer. 
Sunitinib zavira več receptorskih tirozin-kinaz (RTK), vpletenih v rast tumorja, neoangiogenezo in metastatsko napredovanje raka.
• Abnormal muscle breakdown which can lead to kidney problems (rhabdomyolysis). 
• nenormalna razgradnja mišic, ki lahko povzroči težave z ledvicami (rabdomioliza)
Although sunitinib and its primary metabolite were not eliminated through haemodialysis in subjects with ESRD, the total systemic exposures were lower by 47% for sunitinib and 31% for its primary metabolite compared to subjects with normal renal function. 
Čeprav se sunitinib in njegov glavni presnovek ne izločata s hemodializo, je pri bolnikih z ESRD celotna sistemska izpostavljenost manjša za 47 % pri sunitinibu in za 31 % pri njegovem glavnem presnovku v primerjavi z osebami z normalnim delovanjem ledvic.
• High blood pressure. 
• visok krvni tlak
In these paediatric patients without previous exposure to anthracyclines or cardiac irradiation, the maximum tolerated dose (MTD) has been identified (see section 5.1). 
Pri teh pediatričnih bolnikih brez predhodne izpostavljenosti antraciklinom ali obsevanju srca so ugotovili največji odmerek, ki ga bolniki še prenašajo (MTD - maximum tolerated dose) (glejte poglavje 5.1).
The median duration of treatment was 11.1 months (range: 0.4-46.1) for sunitinib treatment and 4.1 months (range: 0.1-45.6) for IFN-α treatment. 
Mediano trajanje zdravljenja je bilo 11,1 meseca (razpon: 0,4-46,1) za zdravljenje s sunitinibom in 4,1 meseca (razpon: 0,1-45,6) za zdravljenje z IFN-.
Because active substances are commonly excreted in human milk and because of the potential for serious adverse reactions in breast-feeding infants, women should not breast-feed while taking Sutent. 
Ker se učinkovine pogosto izločajo v materino mleko in ker obstaja možnost resnih neželenih reakcij pri dojenih otrocih, ženske, ki jemljejo zdravilo Sutent, ne smejo dojiti.
None of these events in the Phase 3 studies were fatal, but rare fatal haematological events, including haemorrhage associated with thrombocytopenia and neutropenic infections, have been reported during postmarketing surveillance. 
Pri nobenem od teh dogodkov v študijah 3. faze ni bilo smrtnih izidov, vendar pa so o redkih hematoloških dogodkih s smrtnim izidom, vključno s krvavitvijo, povezano s trombocitopenijo in nevtropeničnimi okužbami, poročali med nadzorom v obdobju trženja zdravila.
Increases in the QTc interval to over 500 msec were reported in 0.5%, and changes from baseline in excess of 60 msec were reported in 1.1% of the 450 solid tumour patients; both of these parameters are recognised as potentially significant changes. 
O podaljšanju intervala QTc, daljšemu kot 500 milisekund, so poročali pri 0,5 %, o spremembah od izhodišča, večjih od 60 milisekund, pa pri 1,1 % od 450 bolnikov s čvrstimi tumorji; oba parametra veljata za potencialno pomembni spremembi.
What Sutent is and what it is used for What you need to know before you take Sutent How to take Sutent 
Kaj je zdravilo Sutent in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Sutent Kako jemati zdravilo Sutent Možni neželeni učinki
No formal clinical studies of the effect of sunitinib on wound healing have been conducted. 
Formalne klinične študije o vplivu sunitiniba na celjenje ran niso bile izvedene.
Sunitinib and/or its metabolites are excreted in rat milk. 
Sunitinib in/ali njegovi presnovki se pri podganah izločajo v mleko.
Studies in cancer patients have excluded patients with ALT or AST > 2.5 x ULN (upper limit of normal) or > 5.0 x ULN if due to liver metastasis. 
V študije pri bolnikih z rakom niso bili vključeni bolniki z ALT ali AST > 2,5 x ZMN (zgornjo mejo normale) oz. > 5,0 x ZMN, če je šlo za posledico jetrnih metastaz.
All findings occurred at clinically relevant sunitinib plasma exposure levels. 
Vsi izsledki so se pojavili pri izpostavljenosti klinično pomembnim količinam sunitiniba v plazmi.
• Overproduction of thyroid hormones which increases the amount of energy the body uses at rest. 
• prekomerno izločanje ščitničnih hormonov, ki povzročijo, da telo ob mirovanju porabi več energije
Results for ORR are given as percent of subjects with confirmed response with the 95% CI. 
d Rezultati za ORR (objektivni odziv na zdravljenje) so podani kot odstotek bolnikov s potrjenim odzivom z IZ 95 %.
- Gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel, where imatinib (another anticancer medicine) no longer works or you cannot take imatinib. 
- Gastrointestinalni stromalni tumor (GIST), vrsta raka na želodcu in črevesju, kjer zdravljenje z imatinibom (drugim zdravilom proti raku) ni več učinkovito ali imatiniba ne morete jemati.
Hypertension has been reported in association with sunitinib, including severe hypertension (> 200 mmHg systolic or 110 mmHg diastolic). 
V povezavi s sunitinibom so poročali o hipertenziji, vključno s hudo hipertenzijo (sistolični tlak > 200 mmHg ali diastolični tlak > 110 mmHg).
• Complication of severe infection (infection is present in the bloodstream) that can lead to tissue damage, organ failure, and death. 
• zaplet hude okužbe (okužba je prisotna v krvnem obtoku), ki lahko privede do poškodbe tkiva,
The calculated in vitro Ki values for all cytochrome P450 (CYP) isoforms tested (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and CYP4A9/11) indicated that sunitinib and its primary active metabolite are unlikely to induce metabolism, to any clinically relevant extent, of other actives substances that may be metabolised by these enzymes. 
Na podlagi izračunanih in vitro vrednosti Ki za vse testirane izooblike citokromov P450 - CYP (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5 in CYP4A9/11) je malo verjetno, da bi sunitinib in njegov primarni aktivni presnovek imela klinično pomemben vpliv na indukcijo presnove učinkovin, ki se presnavljajo s temi encimi.
Data from non clinical (in vitro and in vivo) studies, at doses higher than the recommended human dose, indicated that sunitinib has the potential to inhibit the cardiac action potential repolarisation process (e.g., prolongation of QT interval). 
Podatki iz predkliničnih študij (in vitro in in vivo) z odmerki, večjimi od priporočenega odmerka za človeka, kažejo, da lahko sunitinib zavre repolarizacijsko fazo srčnega akcijskega potenciala (npr. podaljšanje intervala QT).
This analysis provided a conservative estimate of the treatment effect of sunitinib and supported the primary analysis, demonstrating a hazard ratio of 0.507 (95% CI: 0.350, 0.733), p=0.000193. 
Ta analiza je prispevala konzervativno oceno učinka zdravljenja s sunitinibom in podprla primarno analizo, pri čemer je izkazovala razmerje ogroženosti 0,507 (95 % IZ: 0,350, 0,733), p = 0,000193.
Sunitinib and its primary active metabolite were the major compounds identified in plasma, urine, and faeces, representing 91.5%, 86.4%, and 73.8% of radioactivity in pooled samples, respectively. 
Sunitinib in njegov primarni aktivni presnovek sta glavni spojini v plazmi, urinu in blatu ter predstavljata 91,5 % (plazma), 86,4 % (urin) oz. 73,8 % (blato) radioaktivnosti v kumuliranih vzorcih.
Studies in animals have shown reproductive toxicity including foetal malformations (see section 5.3). 
Študije na živalih so pokazale vpliv na sposobnost razmnoževanja, vključno z malformacijami ploda (glejte poglavje 5.3).
If Sutent is used during pregnancy or if the patient becomes pregnant while on treatment with Sutent, the patient should be apprised of the potential hazard to the foetus. 
Če se zdravilo Sutent uporablja med nosečnostjo ali če bolnica med zdravljenjem z zdravilom Sutent zanosi, jo moramo seznaniti z možnimi nevarnostmi za plod.
The most frequent events included cerebrovascular accident, transient ischaemic attack, and cerebral infarction. 
Med najpogostejšimi dogodki so bili cerebrovaskularni insult, prehodna možganska ishemija in možganski infarkt.
Blood glucose levels in diabetic patients should be checked regularly in order to assess if antidiabetic medicinal product's dosage needs to be adjusted to minimise the risk of hypoglycaemia (see section 4.8). 
Pri sladkornih bolnikih je treba redno preverjati ravni glukoze v krvi, da se oceni, če je treba za zmanjšanje tveganja za hipoglikemijo prilagoditi odmerek antidiabetika (glejte poglavje 4.8).
Patients with signs or symptoms of muscle toxicity should be managed as per standard medical practice (see section 4.4). 
Bolnike z znaki ali simptomi toksičnih učinkov na mišice je treba obravnavati v skladu s standardno zdravniško prakso (glejte poglavje 4.4).
With repeated daily administration, sunitinib accumulates 3- to 4-fold and its primary active metabolite accumulates 7- to 10-fold. 
S ponavljajočo se dnevno uporabo se sunitinib nakopiči 3do 4-kratno, njegov primarni aktivni presnovek pa 7- do 10-kratno.
Dose-limiting cardiotoxicity was observed in the first part of the study which was therefore amended to exclude patients with previous exposure to potentially cardiotoxic therapies (including anthracyclines) or cardiac radiation. 
V prvem delu študije so opazili kardiotoksičnost, ki je omejevala odmerek, zato so iz študije izključili bolnike, ki so bili predhodno izpostavljeni potencialno kardiotoksičnemu zdravljenju (vključno z antraciklini) ali obsevanju srca.
Hypothyroidism may develop during treatment. 
Med zdravljenjem se lahko pojavi hipotiroidizem.
The risk of cardiac adverse drug reactions appeared to be higher in paediatric patients with previous exposure to cardiac irradiation or anthracycline compared to those paediatric patients without previous exposure. 
Tveganje za pojav s srcem povezanih neželenih učinkov zdravila je bilo večje pri pediatričnih bolnikih s predhodno izpostavljenostjo obsevanju srca ali antraciklinu v primerjavi s pediatričnimi bolniki brez predhodne izpostavljenosti.
Systemic exposures after a single dose of sunitinib were similar in subjects with severe renal impairment (CLcr < 30 ml/min) compared to subjects with normal renal function (CLcr > 80 ml/min). 
Sistemske izpostavljenosti po enkratnem odmerku sunitiniba so podobne pri bolnikih s hudo ledvično okvaro (CLcr < 30 ml/min) v primerjavi z osebami z normalnim delovanjem ledvic (CLcr > 80 ml/min).
A total of 59 out of 85 patients (69.4%) from the placebo arm crossed over to open-label sunitinib following disease progression or unblinding at study closure. 
Skupno 59 od 85 bolnikov (69,4 %) iz skupine, ki je prejemala placebo, se je ob napredovanju bolezni ali razkritju šifre ob koncu študije vključilo v odprto študijo s sunitinibom.
Secondary endpoints included TTP, duration of response (DR) and OS. 
Med sekundarnimi opazovanimi dogodki so bili TTP, trajanje odziva (DR - duration of response) in celokupno preživetje (OS).
Other possible dermatological effects may include dryness, thickness or cracking of the skin, blisters, or rash on the palms of the hands and soles of the feet. 
Drugi možni dermatološki učinki lahko vključujejo suho, zadebeljeno ali razpokano kožo, mehurje ali izpuščaj na dlaneh in podplatih.
Increases in lipase activities were transient and were generally not accompanied by signs or symptoms of pancreatitis in subjects with various solid tumours (see section 
Zvečanje aktivnosti lipaze je bilo prehodno in ga pri preskušancih z različnimi čvrstimi tumorji praviloma niso spremljali znaki ali simptomi pankreatitisa (glejte poglavje
Sunitinib treatment was associated with longer survival compared to IFN-α. 
Zdravljenje s sunitinibom je bilo v primerjavi z IFN- povezano z daljšim preživetjem.
How to take Sutent 
Kako jemati zdravilo Sutent
In this study the ORR was 35.8% (95% CI: 26.8% , 47.5 %). 
ORR v tej študiji je znašal 35,8 % (95 % IZ: 26,8 %; 47,5 %).
• Abnormal changes in the brain that can cause a collection of symptoms including headache, confusion, seizures, and vision loss (reversible posterior leukoencephalopathy syndrome). 
• nenormalne spremembe v možganih, ki lahko povzročijo več simptomov, vključno z glavobolom, zmedenostjo, epileptičnimi krči in izgubo vida (sindrom reverzibilne posteriorne levkoencefalopatije)
Additionally, 49% of sunitinib patients had nonfunctioning tumours versus 52% of placebo patients and 92% of patients in both arms had liver metastases. 
Poleg tega je 49 % bolnikov, ki so prejemali sunitinib, imelo nedelujoče tumorje v primerjavi z 52 % bolnikov, ki so prejemali placebo, 92 % bolnikov v obeh skupinah pa je imelo jetrne metastaze.
While you are on this medicine "pyoderma gangrenosum" (painful skin ulceration) or “necrotising fasciitis” (rapidly spreading infection of the skin/soft tissue that may be life-threatening) may occur. 
Med uporabo tega zdravila se vam lahko pojavi ''gangrenozna pioderma'' (boleče razjede na koži) ali ''nekrotizirajoči fasciitis'' (okužba kože/mehkih tkiv, ki se hitro širi in je lahko življenjsko ogrožajoča).
QTc interval prolongation was investigated in a trial in 24 patients, ages 20-87 years, with advanced malignancies. 
Podaljšanje intervala QTc so preučevali v študiji pri 24 bolnikih z napredovalim rakom, starih od 20 do 87 let.
Sutent can cause heart problems. 
Zdravilo Sutent lahko povzroči težave s srcem.
A population pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) analysis was conducted with the scope to extrapolate the PK and key safety and efficacy endpoints of sunitinib in paediatric patients with GIST (aged: 6 years to 17 years). 
Izvedena je bila analiza populacijske farmakokinetike (FK) in farmakokinetike/farmakodinamike (FK/FD) z namenom ekstrapolacije FK in ključnih opazovanih dogodkov glede varnosti in učinkovitosti sunitiniba pri pediatričnih bolnikih z GIST (starih od 6 let do 17 let).
Severe cutaneous reactions have been reported, including cases of erythema multiforme (EM), cases suggestive of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), some of which were fatal. 
Poročali so o hudih kožnih reakcijah, vključno s primeri multiformnega eritema (EM), primeri, ki so nakazovali Stevens-Johnsonov sindrom (SJS) in toksično epidermalno nekrolizo (TEN), od katerih jih je bilo nekaj smrtnih.
ORR (%) 
ORR (%) Vmesni ni ustrezno
It is available in plastic bottles of 30 capsules and in perforated unit dose blisters containing 28 x 1 capsules. 
Zdravilo je na voljo v plastenkah s 30 kapsulami ter v perforiranih enoodmernih pretisnih omotih z 28 kapsulami.
The primary efficacy endpoint was ORR, based on Response Evaluation Criteria in Solid Tumours (RECIST). 
Primarni opazovani dogodek učinkovitosti je bil objektivni odziv na zdravljenje (ORR), ocenjen po merilih RECIST (Response Evaluation Criteria in Solid Tumours).
Serious infections, with or without neutropenia, including some with a fatal outcome, have been reported. 
Poročali so o resnih okužbah z ali brez nevtropenije, vključno z nekaterimi s smrtnim izidom.
Subject did not progress or die [n (%)] Subject observed to have progressed or died [n (%)] 
Pri preskušancu bolezen ni napredovala ali ni umrl [n (%)] Pri preskušancu je bolezen napredovala ali je umrl [n (%)] PFS (tedni)
Patients receiving concomitant treatment with anticoagulants (e.g., warfarin, acenocoumarole) may be periodically monitored by complete blood counts (platelets), coagulation factors (PT/INR), and physical examination. 
Pri bolnikih, ki se sočasno zdravijo z antikoagulanti (npr. varfarin, acenokumarol), se lahko redno spremlja celotna krvna slika (trombociti), koagulacijski faktorji (PČ/INR) in opravi telesni pregled.
• Abnormal blood tests including pancreatic and liver enzymes. 
• nenormalni izvidi krvnih preiskav, vključno z encimi trebušne slinavke in jeter
Population PK analyses indicated that sunitinib apparent clearance (CL/F) was not affected by creatinine clearance (CLcr) within the range evaluated (42-347 ml/min). 
Analize populacijske FK so pokazale, da se navidezni očistek sunitiniba v območju ocenjevanega delovanja ledvic (očistek kreatinina (CLcr) od 42 do 347 ml/min) ne spremeni.
Sunitinib was not permanently discontinued in any of these patients. 
Pri nobenem od teh bolnikov zdravljenja s sunitinibom niso trajno prekinili.
Bleeding. 
Krvavitve.
• Abnormally coloured urine. 
• nenormalno obarvan urin
Changes in the uterus (endometrial atrophy) and bone growth plate (physeal thickening or dysplasia of cartilage) are thought to be related to the pharmacological action of sunitinib. 
Spremembe na maternici (atrofija endometrija) in kostni rastni ploščici (zadebelitev fize ali displazija hrustanca) so domnevno povezane s farmakološkim delovanjem sunitiniba.
Reduced offspring body weights were observed during the preweaning and postweaning periods at 3 mg/kg/day. 
Zmanjšano telesno maso mladičev so opazili v času pred in po odstavitvi pri odmerku 3 mg/kg/dan.
After the interim analysis of efficacy and safety, at the recommendation of the independent Data and Safety Monitoring Board (DSMB), the study was unblinded and patients on the placebo arm were offered open-label sunitinib treatment. 
Po vmesni analizi učinkovitosti in varnosti, je bila na priporočilo neodvisnega odbora za spremljanje podatkov o varnosti (DSMB - data safety monitoring board) študija razkrita in bolnikom v skupini s placebom so ponudili odprto zdravljenje s sunitinibom.
One hundred and 6 patients received at least one 50 mg dose of sunitinib on Schedule 4/2. 
Sto šest (106) bolnikov je dobilo vsaj en 50 mg odmerek sunitiniba po shemi 4/2.
• Influenza-like syndrome. 
• gripi podobni znaki bolezni
A total of 255 patients received sunitinib in the open-label treatment phase of the study, including 99 patients who were initially treated with placebo. 
V fazi odprtega zdravljenja je skupaj 255 bolnikov prejelo sunitinib, vključno z 99 bolniki, ki so bili prvotno zdravljeni s placebom.
Summary of progression-free survival 
Povzetek pri preživetju brez napredovanja bolezni
Thyroid function was monitored prospectively in 2 studies in patients with breast cancer; Sutent is not approved for use in breast cancer. 
Delovanje ščitnice so opazovali prospektivno v 2 študijah pri bolnicah z rakom dojk; zdravilo Sutent ni odobreno za uporabo pri raku dojk.
Metastatic renal cell carcinoma (MRCC) Sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. 
Metastatski karcinom ledvičnih celic (MRCC - metastatic renal cell carcinoma) Zdravilo Sutent je indicirano za zdravljenje napredovalega/metastatskega karcinoma ledvičnih celic (MRCC) pri odraslih.
Sunitinib is metabolised primarily by CYP3A4, the CYP isoform which produces its primary active metabolite, desethyl sunitinib, which is then further metabolised by the same isoenzyme. 
Sunitinib se presnavlja predvsem preko CYP3A4, izooblike CYP, ki tvori njegov primarni aktivni presnovek, desetil sunitinib; ta se potem presnavlja naprej preko istega izoencima.
Cases of serious infection (with or without neutropenia), including cases with fatal outcome, have been reported. 
Poročali so o primerih resnih okužb (z nevtropenijo ali brez nje), vključno s primeri s smrtnim izidom.
Following oral administration in healthy volunteers, the elimination half-lives of sunitinib and its primary active desethyl metabolite are approximately 40-60 hours and 80-110 hours, respectively. 
Razpolovni čas izločanja sunitiniba po peroralni uporabi pri zdravih prostovoljcih je približno 40-60 ur, njegovega primarnega aktivnega desetil-presnovka pa približno 80-110 ur.
Nine of these patients had pulmonary embolisms; 1 was Grade 2 and 8 were Grade 4. 
Devet od teh bolnikov je imelo pljučno embolijo: pri 1 bolniku je bila 2. stopnje in pri 8 bolnikih 4. stopnje.
Sunitinib was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRα and PDGFRβ), VEGF receptors (VEGFR1, VEGFR2, and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). 
Ugotovili so, da sunitinib zavira receptorja rastnega faktorja iz trombocitov (PDGFRα in PDGFRβ), receptorje VEGF (VEGFR1, VEGFR2 in VEGFR3), receptor faktorja matičnih celic (KIT), Fms-ju podobno tirozin-kinazo-3 (FLT3), receptor kolonijo stimulirajočega faktorja (CSF-1R) in receptor nevrotrofičnega faktorja iz celic glije (RET).
The active substance is sunitinib. 
Učinkovina je sunitinib.
If signs or symptoms of SJS, TEN, or EM (e.g., progressive skin rash often with blisters or mucosal lesions) are present, sunitinib treatment should be discontinued. 
Če so prisotni znaki SJS, TEN ali EM (npr. napredujoč kožni izpuščaj, pogosto z mehurji ali lezijami na sluznicah), je treba zdravljenje s sunitinibom prekiniti.
Patients should be advised that they may experience dizziness during treatment with sunitinib. 
Bolnikom je treba svetovati, da jih med zdravljenjem s sunitinibom lahko obide omotica.
Sutent contains the active substance sunitinib, which is a protein kinase inhibitor. 
Zdravilo Sutent vsebuje učinkovino sunitinib, ki je zaviralec protein kinaze.
One hundred six patients (61 patients in the treatment-naïve cohort and 45 patients in the later-line cohort) received treatment with sunitinib orally at 37.5 mg once a day on a continuous daily dosing (CDD) schedule. 
Sto šest bolnikov (61 bolnikov v predhodno nezdravljeni kohorti in 45 bolnikov v kohorti z zdravljenjem kasnejše izbire) je prejemalo peroralno zdravljenje s sunitinibom v odmerku 37,5 mg enkrat na dan po shemi neprekinjenega dnevnega odmerjanja (CDD - Continuous Daily Dosing).